NewslettersHuman Immunology NewsImmune Regulation News TYM-3-98, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Preclinical Antitumor Activity in B-Cell Lymphomas By Jamie Kang - April 29, 2024 0 In vivo, TYM-3-98 showed good pharmaceutical properties and remarkably reduced tumor growth in a human lymphoma xenograft model and a mouse lymphoma model. [Life Sciences] AbstractGraphical Abstract